Sofosbuvir treatment and hepatitis C virus infection

doi:10.4254/wjh.v8.i3.183

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8693)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

556

WORD

206

HTML

3776

Tables (1-4)

224

Sum=4762

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

453

Download

761

Sum=1214

Publishing Process of This Article

Item

Count

Browse

1114

Download

1603

Sum=2717

Jan 28, 2016 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Jan 28, 2016; 8(3): 183-190
Published online Jan 28, 2016. doi: 10.4254/wjh.v8.i3.183

Table 3 Summary of phase 3 study for hepatitis C virus genotype 3-infected patients

Study name	Population	Treatment	Duration (wk)	n	LC (%)	SVR12 (%)
						All	Non-LC	LC
FISSION	Naïve	SOF/RBV	12	183	-	56	-	-
POSITRON	IFN-ineligible/intolerant	SOF/RBV	12	98	15	61	68	21
VALENCE	Naïve	SOF/RBV	24	105	12	93	95	92
FUSION	Experienced	SOF/RBV	12	64	39	30	37	19
			16	63	-	62	63	61
VALENCE	Experienced	SOF/RBV	24	145	32	79	87	62

LC: Liver cirrhosis; SVR12: Sustained virologic response at 12 wk; Naïve: Treatment-naïve; Experienced: Treatment-experienced; SOF: Sofosbuvir; IFN: Interferon; RBV: Ribavirin.

Citation: Nakamura M, Kanda T, Haga Y, Sasaki R, Wu S, Nakamoto S, Yasui S, Arai M, Imazeki F, Yokosuka O. Sofosbuvir treatment and hepatitis C virus infection. World J Hepatol 2016; 8(3): 183-190
URL: https://www.wjgnet.com/1948-5182/full/v8/i3/183.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i3.183